Basilea reported a strong set of interim 2018 results; H118 total revenues grew to CHF59.9m (+30%, H117 CHF46.2m). Notable is Cresemba’s (invasive mould infections) performance; its revenue contribution increased 30% to CHF26.3m (H117 CHF20.3m), which includes royalties on sales of CHF10.8m (H117 CHF5.3m) received from partners. Zevtera (severe bacterial infections) sales remain lacklustre; however, the US opportunity is key and the two required registration ceftobiprole trials (SAB and
21 Aug 2018
Basilea Pharmaceutica - Cresemba growth, pipeline expansion
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Basilea Pharmaceutica - Cresemba growth, pipeline expansion
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
21 Aug 2018 -
Author:
Dr Susie Jana -
Pages:
8
Basilea reported a strong set of interim 2018 results; H118 total revenues grew to CHF59.9m (+30%, H117 CHF46.2m). Notable is Cresemba’s (invasive mould infections) performance; its revenue contribution increased 30% to CHF26.3m (H117 CHF20.3m), which includes royalties on sales of CHF10.8m (H117 CHF5.3m) received from partners. Zevtera (severe bacterial infections) sales remain lacklustre; however, the US opportunity is key and the two required registration ceftobiprole trials (SAB and